Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left" rowspan="2">Test solution</td><td class="align_center" colspan="2">DARPin-associated activity (%)</td></tr><tr class="thead"><td class="align_center">1 h</td><td class="align_center">3 h</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">PBS</td><td class="align_center">99.8 ± 0.2</td><td class="align_center">98.2 ± 0.1</td></tr><tr><td class="align_left">Histidine (500-fold excess)</td><td class="align_center">99.7 ± 0.4</td><td class="align_center">98.7 ± 0.4</td></tr><tr><td class="align_left">Histidine (5000-fold excess)</td><td class="align_center">99.0 ± 0.3</td><td class="align_center">97.7 ± 0.6</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Stability of [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-DARPin 9_29.</div>

Contrast Media & Molecular Imaging

tab2

Table 2

Table 2: Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors 

Table 2 | Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors 